High-Cost Claims Are Destroying Stop Loss Insurance
🚨 STOP-LOSS CRISIS: Self-Funded Health Plans Face $4M+ Gene Therapy Claims While Carriers Secretly Limit Coverage
49% of employers hit $1M+ claims in 2024 (double from 2023). Your "safety net" may not cover the most expensive treatments.
Gene therapies now cost up to $4.25M per patient. Stop-loss insurance wasn't built for this reality - and carriers are responding by limiting exposure through the very product designed to protect you.
📖 CHAPTERS:
0:00 The Stop-Loss Promise Is Breaking
2:15 What Stop-Loss Was Originally Built For
4:30 The Gene Therapy Revolution ($2M+ Treatments)
7:45 Why "It's Rare" Isn't Enough Protection
10:20 What Carriers Are Really Doing
12:10 The Coverage Gap Crisis
This isn't just about expensive drugs - it's about the fundamental breakdown of catastrophic coverage for self-funded employers. With 48 gene therapies approved and FDA fast-tracking more, the math that worked for 40 years is obsolete.
Stop-loss premiums jumped 8-14% annually since 2022. Claims over $3M rose 47% year-over-year. Yet carriers are finding creative ways to limit exposure to multi-million dollar treatments through exclusions, prior authorization barriers, and coverage restrictions.
Every benefits manager needs to understand: the safety net you think you have may not exist when you need it most. This analysis breaks down the real data behind the crisis and what it means for your organization's financial exposure.
🔗 LINKS & RESOURCES:
📧 Newsletter: https://danmccoymd.substack.com/
🐦 Follow on X: https://x.com/docdano
📺 ABOUT THIS CHANNEL:
RocketTools delivers data-driven analysis on healthcare benefits, self-funding strategies, and industry trends affecting employers nationwide.
#StopLoss #SelfFunded #HealthBenefits #GeneTherapy #EmployeeBenefits